MEI Pharma GAAP EPS of 8.46, revenue of 65.3M
MEIP Stock | USD 2.58 0.12 4.44% |
Slightly above 55% of MEI Pharma's retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding MEI Pharma suggests that some traders are interested. MEI Pharma's investing sentiment overview a quick insight into current market opportunities from investing in MEI Pharma. Many technical investors use MEI Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
MEI |
MEI Pharma reports impressive Q1 results with GAAP EPS of 8.46 and revenue of 65.3 million in the first quarter of fiscal year 2024.
Read at seekingalpha.com
MEI Pharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards MEI Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
MEI Pharma Fundamental Analysis
We analyze MEI Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MEI Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MEI Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
MEI Pharma is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
MEI Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MEI Pharma stock to make a market-neutral strategy. Peer analysis of MEI Pharma could also be used in its relative valuation, which is a method of valuing MEI Pharma by comparing valuation metrics with similar companies.
Peers
MEI Pharma Related Equities
ZURA | Zura Bio | 9.65 | ||||
OCUL | Ocular Therapeutix | 3.34 | ||||
TERN | Terns Pharmaceuticals | 2.12 | ||||
PHIO | Phio Pharmaceuticals | 1.07 | ||||
ACHL | Achilles Therapeutics | 1.01 | ||||
INZY | Inozyme Pharma | 0.99 | ||||
VINC | Vincerx Pharma | 0.84 | ||||
ASMB | Assembly Biosciences | 0.20 | ||||
REVB | Revelation Biosciences | 0 | ||||
ABOS | Acumen Pharmaceuticals | 0.00 | ||||
TIL | Instil Bio | 0.00 | ||||
ZVSA | ZyVersa Therapeutics | 0.00 | ||||
KZR | Kezar Life | 0.44 | ||||
HOOK | Hookipa Pharma | 0.47 | ||||
CTMX | CytomX Therapeutics | 0.89 | ||||
SPRO | Spero Therapeutics | 0.93 | ||||
DAWN | Day One | 1.02 | ||||
RNAZ | Transcode Therapeutics | 2.96 | ||||
ATXI | Avenue Therapeutics | 3.23 |
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.